Neuropsychopharmacology Reports (Mar 2023)

Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders

  • Kentaro Fukumoto,
  • Fumitoshi Kodaka,
  • Naomi Hasegawa,
  • Hiroyuki Muraoka,
  • Hikaru Hori,
  • Kayo Ichihashi,
  • Yuka Yasuda,
  • Hitoshi Iida,
  • Kazutaka Ohi,
  • Shinichiro Ochi,
  • Kenta Ide,
  • Naoki Hashimoto,
  • Masahide Usami,
  • Toshinori Nakamura,
  • Hiroshi Komatsu,
  • Tsuyoshi Okada,
  • Tatsuya Nagasawa,
  • Ryuji Furihata,
  • Kiyokazu Atake,
  • Mikio Kido,
  • Saya Kikuchi,
  • Hirotaka Yamagata,
  • Taishiro Kishimoto,
  • Manabu Makinodan,
  • Tadasu Horai,
  • Masahiro Takeshima,
  • Chika Kubota,
  • Takeshi Asami,
  • Eiichi Katsumoto,
  • Akitoyo Hishimoto,
  • Toshiaki Onitsuka,
  • Junya Matsumoto,
  • Kenichiro Miura,
  • Hisashi Yamada,
  • Norio Yasui‐Furukori,
  • Koichiro Watanabe,
  • Ken Inada,
  • Kotaro Otsuka,
  • Ryota Hashimoto

DOI
https://doi.org/10.1002/npr2.12301
Journal volume & issue
Vol. 43, no. 1
pp. 33 – 39

Abstract

Read online

Abstract Aim Treatment guidelines are designed to assist patients and health care providers and are used as tools for making treatment decisions in clinical situations. The treatment guidelines of the Japanese Society of Mood Disorders establish treatment recommendations for each severity of depression. The individual fitness score (IFS) was developed as a simple and objective indicator to assess whether individual patients are practicing treatment by the recommendations of the depression treatment guidelines of the Japanese Society of Mood Disorders. Methods The EGUIDE project members determined the IFS through the modified Delphi method. In this article, the IFS was calculated based on the treatment of depressed patients treated and discharged between 2016 and 2020 at facilities participating in the EGUIDE project. In addition, we compared scores at admission and discharge. Results The study included 428 depressed patients (mild n = 22, moderate/severe n = 331, psychotic n = 75) at 57 facilities. The mean IFS scores by severity were statistically significantly higher at discharge than at admission with moderate/severe depression (mild 36.1 ± 34.2 vs. 41.6 ± 36.9, p = 0.49; moderate/severe 50.2 ± 33.6 vs. 55.7 ± 32.6, p = 2.1 × 10–3; psychotic 47.4 ± 32.9 versus 52.9 ± 36.0, p = 0.23). Conclusion We developed the IFS based on the depression treatment guideline, which enables us to objectively determine how close the treatment is to the guideline at the time of evaluation in individual cases. Therefore, the IFS may influence guideline‐oriented treatment behavior and lead to the equalization of depression treatment in Japan, including pharmacotherapy.

Keywords